CDMO manufacturing complex injectables, ophthalmics and biologics for global pharma clients, spun off from Strides Pharma.
CDMO manufacturing complex injectables, ophthalmics and biologics for global pharma clients, spun off from Strides Pharma.
In one line: A newly independent Indian CDMO.
Moat: narrow (regulatory licence, process know-how). Specialized regulated manufacturing facilities for complex dosage forms are costly for new entrants.
Headquarters: Bengaluru, India · Employees: 2,289
Size OneSource Specialty Pharma (ONESOURCE.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $1.95B, the 382nd largest of 1,066 India companies the cockpit tracks. Shares closed at ₹1,586 on 18 Nov 2026.
Performance Over six months the shares fell 14.5%, against -1.3% for the median peer and +3.8% for the India market (cap-weighted) — 7th lowest of 21 in its peer set.
Growth Revenue grew 10.7% over the last twelve months (peer median +8.7%); the operating margin is 6.4% (peer median 20.9%).
Valuation It trades at 44.6× forward earnings against a peer median of 20.0× (4th most expensive of 17).
Capital Return on invested capital runs 14.7 points below its cost of capital (15.8% WACC).
Next results Next results expected around 22 Jan 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹16.8B | ₹14.2B | ₹14.4B | ₹1.72B | ₹387M |
| Revenue growth | — | -2% | +740% | +344% | — |
| Gross profit | ₹5.92B | ₹3.85B | ₹4.53B | -₹1.94B | -₹1.48B |
| EBITDA | ₹3.96B | ₹2.75B | ₹4.65B | -₹1.98B | -₹2.00B |
| Net income | -₹16.2M | -₹738M | -₹180M | -₹3.91B | -₹8.00B |
| Free cash flow | n/a | -₹6.80B | -₹3.39B | -₹2.71B | -₹3.09B |
| Capital expenditure | n/a | ₹5.69B | ₹1.28B | ₹638M | ₹440M |
| Total debt | ₹17.5B | ₹15.0B | ₹9.42B | ₹5.71B | ₹8.64B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| OneSource Specialty Pharma ONESOURCE.NS | $1.95B | -14% | +11% | 6% | 44.6× | n/a |
| Piramal Pharma PPLPHARMA.NS | $3.40B | +38% | +9% | 3% | 150.8× | n/a |
| Syngene International SYNGENE.NS | $1.88B | -8% | -6% | 13% | 70.7× | 36.4% |
| Gland Pharma GLAND.NS | $5.71B | +44% | +22% | 21% | 39.3× | 20.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ONESOURCE.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +16.1% | +0.3% | 3rd highest of 21 |
| 6-month return | -14.5% | -1.3% | 7th lowest of 21 |
| Distance from 52-week high | -17.3% | -28.8% | 5th highest of 21 |
| Revenue growth (TTM) | +10.7% | +8.7% | 10th highest of 20 |
| Operating margin | 6.4% | 20.9% | 5th lowest of 20 |
| Forward P/E | 44.6× | 20.0× | 4th most expensive of 17 |
| ROIC minus cost of capital | -14.7 pp | +1.6 pp | 4th lowest of 20 |
| EV / EBITDA | 50.3× | 15.0× | 2nd most expensive of 10 |
| Net debt / EBITDA | 4.3× | 1.1× | most indebted of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| OneSource Specialty Pharma ONESOURCE.NS | India | $1.95B | -14% | +11% | 6% | 44.6× | n/a | n/a |
| Biohaven BHVN | United States | $1.95B | +46% | n/a | n/a | n/a | n/a | n/a |
| Harmony Biosciences HRMY | United States | $1.94B | +6% | +20% | 22% | 8.6× | -10.5% | +40.3% |
| Jinyu Bio-Technology 600201.SS | China | $1.93B | -21% | +22% | 10% | 59.0× | 23.4% | -2.5% |
| Tsumura & 4540.T | Japan | $1.93B | +6% | +13% | 18% | 10.4× | n/a | n/a |
| Grand Pharmaceutical 0512.HK | Hong Kong | $1.93B | -25% | +7% | 13% | 9.4× | 1.2% | +14.1% |
| Shilpa Medicare SHILPAMED.NS | India | $1.91B | +94% | +37% | 21% | 54.3× | n/a | n/a |
| Eris Lifesciences ERIS.NS | India | $1.98B | 0% | +11% | 26% | 27.9× | 26.3% | +20.9% |
| Alivus Life Sciences ALIVUS.NS | India | $1.90B | +36% | +8% | 31% | 23.8× | 20.1% | +6.2% |
| InnoCare Pharma 9969.HK | Hong Kong | $2.01B | -10% | +146% | 35% | 32.2× | -2.0% | +341.1% |
| Hanall Biopharma 009420.KS | South Korea | $2.01B | +12% | +5% | 3% | n/a | n/a | n/a |
| Pfizer PFIZER.NS | India | $1.88B | -20% | +12% | 34% | 21.9× | 11.2% | +2.4% |
| Anhui Anke Biotechnology (Group) 300009.SZ | China | $1.88B | -12% | -9% | 30% | 18.1× | 8.0% | +9.3% |
| Fujian Cosunter Pharmaceutical 300436.SZ | China | $2.02B | -45% | 0% | -47% | n/a | n/a | n/a |
| Tibet Rhodiola Pharmaceutical 600211.SS | China | $1.87B | -8% | +13% | 27% | 12.5× | -1.2% | +16.7% |
| Zhejiang Jiuzhou Pharmaceutical 603456.SS | China | $2.03B | +19% | -1% | 14% | 16.9× | 1.7% | +15.7% |
| Cohance Lifesciences COHANCE.NS | India | $1.87B | +7% | +14% | 2% | 96.3× | n/a | n/a |
| Nanjing King-friend Biochemical Pharmaceutical 603707.SS | China | $2.03B | -3% | +9% | 14% | 25.9× | 5.1% | +6.4% |
| Henan Lingrui Pharmaceutial 600285.SS | China | $2.04B | +9% | +5% | 22% | 15.9× | -4.7% | +10.6% |
| CSPC Hunan Jingfeng Pharmaceutical 000908.SZ | China | $1.85B | -38% | +5% | -18% | n/a | n/a | n/a |
| Dermapharm DMP.DE | Germany | $1.85B | -29% | +2% | 21% | 13.2× | -3.4% | +8.0% |